About US
Contact us
-
After Merck's flashpoint IRA lawsuit, Biogen CEO and others register their own complaintsMerck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, the leaders of other companies2023/6/6
-
GSK's adult RSV shot Arexvy nabs European approval weeks after US endorsementAfter GSK nabbed a coveted world-first approval for its adult respiratory syncytial virus (RSV) vaccine in the U.S., it has scoredthe same title in Europe withArexvy. Theauthorizationcovers adults2023/6/6
-
Amgen extends restraining order in Horizon pursuit as court's scheduling comes into focusWhen Amgenrevealed its intention to buy Horizon Therapeutics in 2022's largest biopharma buyout, executives with the California-based drugmakersaidthey hoped to close the deal in the first half of 202023/6/1
-
ASCO: Merck's Keytruda trips in EGFR lung cancer as Roche's Tecentriq fails in kidney cancerThe PD-1/L1 inhibitor class of drugs has vastly improved care for many patients with cancer, but some meds in the class have posted trial failures lately. At the American Society of Clinical Oncology2023/6/1
-
After breakup with Otsuka, Akebia finds new partner for oral anemia drug in EuropeAkebia Therapeutics has found a new partner in Europe for oral anemia drug Vafseo in chronic kidney disease. But the deal is smaller than the company's prior pact with Otsuka. Medice Arzn2023/5/29
-
Johnson & Johnson takes another step in CAR-T race with Bristol Myers in multiple myelomaIn a race with Bristol Myers Squibb to advance cell therapies to treat patients at an earlier stage of multiple myeloma, Johnson & Johnson has hit another milepost. J&J and co-dev2023/5/29
-
Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth chargeBiopharma companies know well the pain of a patent cliff.But how about a COVID cliff? With demand for vaccines and other COVID-19 products plummeting, drugmakers who thr2023/5/25
-
Bayer's blockbuster hopeful Nubeqa, AstraZeneca's Forxiga pick up nods from England's NICEBayer has blockbuster hopes for prostate cancer med Nubeqa, and a newendorsement from the U.K.’s National Institute for Health and Care Excellence (NICE) provides another milestonetoward that goal.2023/5/25
-
Intercept's NASH dreams may be dashed after FDA panel votes against Ocaliva's approval bidIt looks like Intercept Pharmaceuticals’ Ocaliva still has a tough road ahead in nonalcoholic steatohepatitis (NASH) after a panel of FDA advisers voiced concerns with the company's application packa2023/5/23
-
Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin diseaseThe first FDA-approved treatment for a rare, devastating skin disease has arrived in Krystal Biotech’s Vyjuvek. The disease, called dystrophic epidermolysis bullosa (DEB), is hallmarked b2023/5/23